Literature DB >> 32452027

Dose calculation errors as a component of failing IROC lung and spine phantom irradiations.

Sharbacha S Edward1,2,3, Mallory C Glenn1,2,3, Christine B Peterson1,4, Peter A Balter1,3, Julianne M Pollard-Larkin1,3, Rebecca M Howell1,3, David S Followill1,2,3, Stephen F Kry1,2,3.   

Abstract

PURPOSE: Between July 2013 and August 2019, 22% of the imaging and radiation oncology core (IROC) spine, and 15% of the moving lung phantom irradiations have failed to meet established acceptability criteria. The spine phantom simulates a highly modulated stereotactic body radiation therapy (SBRT) case, whereas the lung phantom represents a low-to-none modulation moving target case. In this study, we assessed the contribution of dose calculation errors to these phantom results and evaluated their effects on failure rates.
METHODS: We evaluated dose calculation errors by comparing the calculation accuracy of various institutions' treatment planning systems (TPSs) vs IROC-Houston's previously established independent dose recalculation system (DRS). Each calculation was compared with the measured dose actually delivered to the phantom; cases in which the recalculation was more accurate were interpreted as a deficiency in the institution's TPS. A total of 258 phantom irradiation plans (172 lung and 86 spine) were recomputed.
RESULTS: Overall, the DRS performed better than the TPSs in 47% of the spine phantom cases. However, the DRS was more accurate in 93% of failing spine phantom cases (with an average improvement of 2.35%), indicating a deficiency in the institution's treatment planning system. Deficiencies in dose calculation accounted for 60% of the overall discrepancy between measured and planned doses among spine phantoms. In contrast, lung phantom DRS calculations were more accurate in only 35% and 42% of all and failing lung phantom cases respectively, indicating that dose calculation errors were not substantially present. These errors accounted for only 30% of the overall discrepancy between measured and planned doses.
CONCLUSIONS: Dose calculation errors are common and substantial in IROC spine phantom irradiations, highlighting a major failure mode in this phantom and in clinical treatment management of these cases. In contrast, dose calculation accuracy had only a minimal contribution to failing lung phantom results, indicating that other failure modes drive problems with this phantom and similar clinical treatments.
© 2020 American Association of Physicists in Medicine.

Entities:  

Keywords:  IROC; TPS dose calculation; lung phantom; phantom irradiation; spine phantom

Mesh:

Year:  2020        PMID: 32452027      PMCID: PMC7686159          DOI: 10.1002/mp.14258

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  15 in total

1.  Uncertainty analysis of absorbed dose calculations from thermoluminescence dosimeters.

Authors:  T H Kirby; W F Hanson; D A Johnston
Journal:  Med Phys       Date:  1992 Nov-Dec       Impact factor: 4.071

2.  Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group.

Authors:  Andrea Molineu; David S Followill; Peter A Balter; William F Hanson; Michael T Gillin; M Saiful Huq; Avraham Eisbruch; Geoffrey S Ibbott
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

3.  Examining credentialing criteria and poor performance indicators for IROC Houston's anthropomorphic head and neck phantom.

Authors:  Mallory E Carson; Andrea Molineu; Paige A Taylor; David S Followill; Francesco C Stingo; Stephen F Kry
Journal:  Med Phys       Date:  2016-12       Impact factor: 4.071

4.  Credentialing results from IMRT irradiations of an anthropomorphic head and neck phantom.

Authors:  Andrea Molineu; Nadia Hernandez; Trang Nguyen; Geoffrey Ibbott; David Followill
Journal:  Med Phys       Date:  2013-02       Impact factor: 4.071

5.  Technical Report: Reference photon dosimetry data for Varian accelerators based on IROC-Houston site visit data.

Authors:  James R Kerns; David S Followill; Jessica Lowenstein; Andrea Molineu; Paola Alvarez; Paige A Taylor; Francesco C Stingo; Stephen F Kry
Journal:  Med Phys       Date:  2016-05       Impact factor: 4.071

6.  Treatment Planning System Calculation Errors Are Present in Most Imaging and Radiation Oncology Core-Houston Phantom Failures.

Authors:  James R Kerns; Francesco Stingo; David S Followill; Rebecca M Howell; Adam Melancon; Stephen F Kry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-04       Impact factor: 7.038

7.  Radiation Therapy Deficiencies Identified During On-Site Dosimetry Visits by the Imaging and Radiation Oncology Core Houston Quality Assurance Center.

Authors:  Stephen F Kry; Lainy Dromgoole; Paola Alvarez; Jessica Leif; Andrea Molineu; Paige Taylor; David S Followill
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-08-24       Impact factor: 7.038

8.  Differences in the patterns of failure between IROC lung and spine phantom irradiations.

Authors:  Sharbacha S Edward; Paola E Alvarez; Paige A Taylor; H Andrea Molineu; Christine B Peterson; David S Followill; Stephen F Kry
Journal:  Pract Radiat Oncol       Date:  2020-05-12

9.  Agreement Between Institutional Measurements and Treatment Planning System Calculations for Basic Dosimetric Parameters as Measured by the Imaging and Radiation Oncology Core-Houston.

Authors:  James R Kerns; David S Followill; Jessica Lowenstein; Andrea Molineu; Paola Alvarez; Paige A Taylor; Stephen F Kry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-02       Impact factor: 7.038

10.  Credentialing for participation in clinical trials.

Authors:  David S Followill; Marcia Urie; James M Galvin; Kenneth Ulin; Ying Xiao; Thomas J Fitzgerald
Journal:  Front Oncol       Date:  2012-12-26       Impact factor: 6.244

View more
  1 in total

1.  Photon beam modeling variations predict errors in IMRT dosimetry audits.

Authors:  Mallory C Glenn; Fre'Etta Brooks; Christine B Peterson; Rebecca M Howell; David S Followill; Julianne M Pollard-Larkin; Stephen F Kry
Journal:  Radiother Oncol       Date:  2021-11-05       Impact factor: 6.280

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.